Traders should monitor for immediate downward pressure on IMA shares due to significant dilution from deeply discounted warrants. The low exercise price of $0.001 means near-certain exercise, effectively adding ~5.77 million new shares at minimal cost, which could weigh on valuation despite the capital infusion.
IMA drugs
IMA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $6.05entry
- T+1 · 7mo ago −5.29%α −6.50% · $5.73
- T+5 · 7mo ago −0.83%α −4.12% · $6.00
- T+20 · 6mo ago −7.27%α −15.00% · $5.61
- T+60 · 4mo ago −2.07%α −10.99% · $5.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImageneBio (IMA) announced a $30 million private placement led by Coastlands Capital, with proceeds aimed at advancing its IMG-007 program in alopecia areata and atopic dermatitis. The offering includes pre-funded warrants exercisable at $0.001 per share, representing immediate economic dilution to existing shareholders.
Key Financial Metrics
Key Facts
- ImageneBio raised approximately $30 million in a private placement through pre-funded warrants.
- Pre-funded warrants for 5,770,335 shares were sold at $5.199 per unit, exercisable at $0.001 per share.
- Proceeds will fund development of IMG-007 in alopecia areata and late-stage atopic dermatitis trials.
- The placement was led by new investor Coastlands Capital, with participation from Trails Edge Capital, Omega Funds, and OrbiMed.
- Shares underlying the warrants are unregistered and subject to resale registration rights.
Financial Impact
Approximately $30 million in gross proceeds, with issuance of 5.77 million pre-funded warrants, creating immediate dilution risk.
Risk Factors
- High dilution from pre-funded warrants with nominal exercise price
- Market conditions may pressure share price ahead of warrant settlement
- Clinical timelines for IMG-007 remain uncertain despite funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272360 |
Track record
10 reports on IMA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Viewing Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers